Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* written informed consent~* males and non-pregnant, non-lactating females~* BMI 19.0-32.0~* willing to abide by contraceptive requirements~* normal vitals~* willing to abide by study procedures and restrictions~Exclusion Criteria:~* clinically significant medical condition or medical history or psychiatric condition or history of psychiatric condition~* abnormal cardiac finding, or laboratory/urinalysis abnormality at screening~* known family history of sudden death or long QT syndrome, family or personal history of QT prolongation, or arrhythmia that required medical intervention~* current participation in any other investigational drug study or participation in an investigational drug study within 3 months of screening visit~* use of prescription, OTC, or herbal medications during study or use of any specified medications within 30 days prior to study~* Recent or current history of alcohol or drug abuse~* Regular use of tobacco or nicotine products~* Positive serology for HBV, HCV, or HIV~* history of severe adverse reaction to or known sensitivity to any drug~* pregnant, lactating, or planning to become pregnant within 30 days of the study. Male subjects with pregnant female partners are excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Galidesivir (Type: EXPERIMENTAL): Galidesivir IV infusion
- placebo (Type: PLACEBO_COMPARATOR): Placebo IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).